EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Impact of Solanum surettense on membrane bound Na+/K+ ATPase and in vivo anti oxidants activity on isoproterenol induced myocardial injury in rats

Chitikela P Pullaiah, S. Dhanunjaya, GV. Narasimha Kumars, D. Pichaiah, M. Venkateswarlu, D Ranganayakulu

The Journal of Phytopharmacology · 2015-06-25 · 4 (3) · 139-142

DOI: 10.31254/phyto.2015.4302 ↗
AbstractBibliografische Angaben

Abstract

The present study was designed to evaluate the cardio protective potential of ethanolic extract of Solanum surettense a warm-climate annual herb, on isoproterenol-induced Myocardial Infarction (MI) in rats. Five groups of albino rats, each comprising six animals, were selected for this study. Group I served as a control, Group II rats were given isoproterenol (ISO) (85mg/kg subcutaneously), and Group III rats were treated with propranolol 10mg/kg as standard treatment. Groups IV and V rats were given ESS (200 mg/kg and 400 mg/kg, respectively) along with isoproterenol (85mg/kg). At end of the study cardiac biomarkers like CK-MB and LDH were estimated to accesses cardio protection. The protective effect of heart is also accessed by estimation of membrane bound Na+ /K+ATPase and tissue antioxidant enzymes like SOD, Catalase and GSH. ESS pre treated animals in various doses significantly decreased the levels of CK-MB and LDH when compared with ISO treated animal. The dose of 400 mg/kg has shown significant protection than 200 mg/kg of ESS i.e. dose dependent cardio protection. The study confirms the cardio protective potential of ethanolic extract of Solanum surettense against isoproterenol-induced biochemical alterations in rats.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →